Hormonal
SGLT2 inhibitors (specifically empagliflozin and dapagliflozin) reduce liver fat content and may improve fibrosis markers in patients with Type 2 Diabetes, offering a cardioprotective and renoprotective alternative to GLP-1 agonists.
SGLT2 inhibitors (like empagliflozin or dapagliflozin) are effective for reducing liver fat and fibrosis in diabetic patients. They are particularly recommended for patients who also have heart failure or kidney disease, as these drugs offer significant protective benefits for these organs. They are a viable alternative to GLP-1 agonists, especially if injections are not preferred.
empagliflozin... has shown positive effects regarding liver fat content... and liver fibrosis... dapagliflozin... showed positive effects regarding steatosis and fibrosis... These agents have been shown to exhibit renal benefits in patients with chronic kidney disease.
Why this rating
Supported by multiple trials (EMPA-REG, DEAN, EFFECT-II) cited.
Source
Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
Emmanouil S. Koullias et al. · Journal of Clinical and Translational Hepatology · 2022
DOI 10.14218/jcth.2021.00564
More from this paper
- GLP-1 receptor agonists (specifically liraglutide and semaglutide) significantly improve histological features of NASH (steatohepatitis resolution) and reduce liver fat content in patients with Type 2 Diabetes, though they may not consistently improve fibrosis.Good
- Pioglitazone (a PPAR-gamma agonist) significantly improves liver inflammation and steatosis in NASH patients, including those with Type 2 Diabetes, but is limited by side effects like weight gain and heart failure risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →